Finding, qualifying and using veterinary journals, USDA and FDA records, conference proceedings and field data in invalidity challenges

1. Introduction

Animal health is a patent-intensive field. Veterinary pharmaceuticals, parasiticides, vaccines, diagnostics, nutritional products, feed additives, genetic technologies and delivery devices for companion animals and livestock all attract patent protection and they generate commercially significant disputes, including generic and biosimilar-style competition, formulation and dosing-regimen patents and method-of-treatment claims. The invalidity case against such patents often depends on a body of prior art that is different in character from the material patent searchers use in other fields. Much of it is published in veterinary journals, extension bulletins, government research reports, regulatory summaries, conference proceedings and theses that are not indexed in the databases that general patent searches rely on.

This article explains how veterinary literature and United States Department of Agriculture (USDA) research can be found and used as prior art in invalidity challenges, primarily under United States law, with some notes for European practice. It covers the legal framework (anticipation, obviousness, enablement of prior art and the “printed publication” standard), the principal source categories, how to establish public accessibility and dates and how the evidence is used in district court, in inter partes review (IPR) and in ex parte reexamination. It is a general guide, not legal advice and the case law and agency practice cited should be verified before use.

2. Why animal health prior art is distinctive

  • Research is decentralised and academic. A great deal of veterinary research takes place at university colleges of veterinary medicine, state agricultural experiment stations, USDA Agricultural Research Service (ARS) laboratories and in the clinical practice of veterinarians. The first public disclosure of a technique often appears in a journal that few patent examiners read, or in a conference abstract.
  • Human-medicine overlap. Many veterinary drugs and methods are adaptations of human medicine and many veterinary studies test established compounds in new species or for new indications. Obviousness arguments therefore often combine human-health prior art with veterinary literature and the question is whether a skilled veterinary scientist would have been motivated to apply one to the other, with a reasonable expectation of success.
  • Species-specific variability. Differences in physiology, pharmacokinetics, disease biology and husbandry across species make the “reasonable expectation of success” analysis highly fact-specific. Patentees often argue that results in one species do not predict results in another and the challenger needs species-specific evidence.
  • Regulatory pathways generate public records. Animal drugs are regulated by the FDA Center for Veterinary Medicine (CVM) and biologics such as vaccines by the USDA Animal and Plant Health Inspection Service (APHIS) Center for Veterinary Biologics (CVB), with some products overlapping other agencies (for example, the EPA for certain pesticides applied to animals). These pathways create public documents, such as approval summaries, labels and notices, that may qualify as prior art.
  • Agricultural practice and public use. In livestock and poultry, field use, extension recommendations and industry practice can precede formal publication, which opens routes to public use and on-sale arguments in addition to printed publications.
  • Government research. USDA’s intramural and extramural research programs produce a large body of reports, bulletins, datasets and project descriptions that are publicly available, sometimes before and sometimes long after the research is reported in journals.

3. The legal framework (United States)

3.1 Prior art categories under 35 U.S.C. § 102

For patents subject to the first-inventor-to-file provisions of the America Invents Act (applications with an effective filing date on or after 16 March 2013), § 102(a)(1) makes prior art any invention that was “patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.” Section 102(a)(2) covers certain earlier-filed, later-published patent documents and applications. The grace period in § 102(b)(1) excepts disclosures made one year or less before the effective filing date by the inventor or by another who obtained the subject matter from the inventor and certain subsequent third-party disclosures after an inventor’s public disclosure. Older patents are governed by pre-AIA § 102, which has different categories (including § 102(b) one-year statutory bars and § 102(a), (e) and (g)). Always establish which regime applies.

For veterinary and USDA material, the most relevant categories are:

  • Printed publications: journal articles, theses, bulletins, reports, abstracts, posters, proceedings, regulatory summaries, labels, patents and published patent applications.
  • Public use and on-sale: field trials without confidentiality, commercial sales of products or services, licensed biologics, extension demonstrations and offers for sale. Under Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 139 S. Ct. 628 (2019), a commercial sale to a third party who is obligated to keep the invention confidential can still trigger the on-sale bar under the AIA.
  • Patents and published applications, including USDA’s own patents and applications, which are prior art under § 102(a)(1) and (a)(2).

3.2 What makes something a “printed publication”

The touchstone is public accessibility. A reference is a printed publication if it was disseminated or otherwise made available in a way that persons interested and ordinarily skilled in the subject matter, exercising reasonable diligence, could locate it. Actual public access is not required; the question is whether the document was sufficiently accessible. Relevant authorities include In re Hall, 781 F.2d 897 (Fed. Cir. 1986) (a thesis cataloged and indexed in a university library was publicly accessible); In re Klopfenstein, 380 F.3d 1345 (Fed. Cir. 2004) (a poster presentation displayed for days at a conference without indexing or distribution was held a printed publication, on the facts, on a multi-factor analysis); Cordis Corp. v. Boston Scientific Corp., 561 F.3d 1319 (Fed. Cir. 2009) (a thesis on file in a university library was accessible despite limited indexing, on the record); Blue Calypso, LLC v. Groupon, Inc., 815 F.3d 1331 (Fed. Cir. 2016) (the analysis for presentations and other materials is fact-intensive); and Voter Verified, Inc. v. Premier Election Solutions, Inc., 698 F.3d 1374 (Fed. Cir. 2012) (a web-based document’s accessibility was assessed on the evidence). Factors courts consider include the length of time the document was displayed, its expected audience, the expertise of the intended audience, the existence of reasonable expectations that the material would not be copied and the ease of copying.

The date a document became publicly accessible, not the date it was written, controls. A document that was never indexed and was available only to a few people may fail the test; a document in a major library catalog or an indexed database will normally satisfy it.

3.3 Anticipation and the enablement of prior art

A reference anticipates a claim only if it discloses each limitation, arranged as claimed, in a manner that would enable a skilled person to practise the invention without undue experimentation. Prior art publications are presumed enabling and the patentee bears the burden of rebutting the presumption with evidence (In re Antor Media Corp., 689 F.3d 1282 (Fed. Cir. 2012)). Inherent anticipation is possible where the missing characteristic is necessarily present in the prior art, even though the prior art did not recognise it (Schering Corp. v. Geneva Pharmaceuticals, Inc., 339 F.3d 1373 (Fed. Cir. 2003); In re Montgomery, 677 F.3d 1375 (Fed. Cir. 2012)), but mere probability or possibility is insufficient.

In veterinary cases, anticipation arguments often turn on whether the earlier publication disclosed the same species, the same dose and regimen, or the same indication. Where a prior study discloses a method of treatment in cattle and the claim is to the same treatment of cattle, the question is largely about disclosure. Where the claim is to a different species, the argument shifts to obviousness.

3.4 Obviousness

Obviousness under § 103 is determined under Graham v. John Deere Co., 383 U.S. 1 (1966): the scope and content of the prior art, the differences between the prior art and the claims, the level of ordinary skill in the art and objective indicia of non-obviousness (secondary considerations). KSR International Co. v. Teleflex Inc., 550 U.S. 398 (2007), rejected a rigid teaching-suggestion-motivation test in favour of a flexible approach that considers predictable variation, design incentives and market pressures and “obvious to try” reasoning where there are a finite number of identified, predictable solutions. For veterinary patents, the common obviousness case patterns are:

  • Species extrapolation. A compound or method is known for humans or one animal species and the claim covers its use in another species. The challenger must show motivation and a reasonable expectation of success, usually supported by veterinary literature showing similar pharmacology or disease biology.
  • Formulation and dosing. The active ingredient is known and the claims cover a particular formulation, concentration, dose, frequency, duration or route. The case relies on veterinary dosing literature, approved labels and formulation references.
  • Combination products. Two known actives are combined, as in a broad-spectrum parasiticide. The challenger relies on literature showing each active separately and on motivation to combine and the patentee relies on unexpected synergy.
  • Vaccines and biologics. Antigens, adjuvants, delivery platforms and vaccination schedules are known individually and the claims cover a particular combination or schedule. USDA licensing records and veterinary immunology journals are prime sources.
  • Diagnostics. Known biomarkers or assay formats are applied to a new species or sample type.
  • Feed and nutrition. Known additives are used in a known diet at a known inclusion rate, or at a rate in a “range” that overlaps prior art. Overlapping ranges generally give rise to a presumption of obviousness (In re Peterson, 315 F.3d 1325 (Fed. Cir. 2003)).

3.5 Written description, enablement and other grounds that interact with prior art

Prior art is the main invalidity theory, but veterinary patents are also vulnerable to § 112 challenges, for example claims to broad genera of compounds or antibodies without sufficient disclosure (see Amgen Inc. v. Sanofi, 598 U.S. 594 (2023), on enablement of broad functional genus claims). Veterinary literature can support these challenges as well, by showing the state of the art at the time of filing and the unpredictability of species-specific results.

4. The principal categories of prior art

4.1 Veterinary and animal-science journals

Peer-reviewed veterinary and animal-science journals are the core of the literature. They include journals in veterinary medicine, parasitology, immunology, pharmacology and toxicology, microbiology, animal nutrition and production, as well as species-specific journals. Characteristics to keep in mind:

  • Dates. Journals have several dates: submission, acceptance, online-first publication and issue date. Prior art status generally follows the date of public availability. For an online-first article, that is typically the online publication date. For print-only older volumes, it may be the issue date or the date of receipt by a library. Establish the earliest provable date for each reference and expect the patentee to scrutinise it.
  • Authentication. Obtain a certified or authenticated copy from the publisher or a library, with a declaration from a custodian of records (a librarian or publisher representative) on the date of publication and the means of dissemination, where the date is contested.
  • Corrections and retractions. Check for errata, corrections and retractions, which may affect the weight of the reference.
  • Supplementary materials. Supplemental data hosted by the publisher may or may not have been available at the same time as the article. Verify their dates separately if you rely on them.
  • Language. Foreign-language veterinary journals are legitimate prior art. A certified translation is needed for litigation or for filing with the Patent Trial and Appeal Board.

4.2 Textbooks, formularies and reference works

Standard veterinary pharmacology texts, drug handbooks (formularies), parasitology and infectious disease references and practice guidelines can supply evidence of the state of the art, the knowledge of a skilled person and routine dosing practice. Ensure that you cite the edition in force before the effective filing date and have evidence of its date and availability. Clinical guidelines from professional associations can show an accepted standard of care.

4.3 USDA research, reports and records

USDA is both a major generator of animal-health research and a publisher of research records. The most relevant sources include:

  • Agricultural Research Service (ARS). ARS scientists publish in peer-reviewed journals and ARS also releases technical bulletins, annual reports for research projects and datasets. ARS research units address zoonotic and livestock diseases, parasitology, animal genomics, nutrition and animal products.
  • National Agricultural Library (NAL) and its catalogs. NAL maintains the AGRICOLA bibliographic database, PubAg and the institutional repositories for USDA-funded publications and data. The availability of a document in NAL’s catalog and the dates of indexing, are strong evidence of public accessibility and date.
  • NIFA and CRIS project records. The National Institute of Food and Agriculture and its predecessors maintain project descriptions and progress reports for funded research. These records can be prior art, or they can corroborate dates and the state of knowledge, although the level of technical detail varies and many are summaries rather than enabling disclosures.
  • APHIS Veterinary Services and the Center for Veterinary Biologics. CVB regulates the licensing of veterinary biologics. Public records can include product lists, licensing and permit notices, veterinary biologics memoranda and notices and information on conditional licenses. The detail available publicly is often limited because manufacturers’ data are confidential business information, so check what is actually public.
  • USDA patents and applications. USDA, through ARS and other agencies, files patent applications on its own inventions. These are prior art as of their publication or issue dates (and as of their effective filing dates under § 102(a)(2)) and may also form part of a family of related patents that discuss the state of the art.
  • Extension and outreach materials. Land-grant university cooperative extension services publish bulletins and fact sheets for producers, often stating recommended practices (dosing, vaccination programs, parasite control). These are among the best evidence of what was standard practice and are frequently dated and archived.
  • Government theses and reports in NTIS and agency archives. Older USDA technical reports may be cataloged in the National Technical Information Service or in library archives.

Caution: A USDA web page or database entry that is undated, regularly updated or subsequently revised is not good evidence of what was public at a given date. Use archived copies (for example, from a web archive with proper authentication), library catalog records, publication dates on the face of the document and custodian declarations to prove the date and content as of the critical date.

4.4 FDA Center for Veterinary Medicine records

  • Freedom of Information (FOI) Summaries for approved new animal drug applications (NADAs and ANADAs) typically describe the drug, indications, dosage, the pivotal studies and the safety data. They can be highly relevant to dose, species and regimen and they are dated.
  • Approved labels and package inserts. Labeling discloses the approved indications, dose, route and warnings. Labels are published and widely distributed and are often cited as prior art in obviousness analyses for formulation and dosing patents. Be sure to cite the version of the label in effect at the relevant date.
  • The FDA “Green Book” (Approved Animal Drug Products). It lists approved animal drug products, sponsors and patent information for products with patents listed under the Generic Animal Drug and Patent Term Restoration Act. Historic editions can show what was approved and available and by when.
  • Federal Register notices and public guidance. Notices of approval, withdrawal and guidance documents (including VICH guidelines adopted by FDA) are dated and public.
  • Public study reports and “Summary Basis”-type documents. Where FDA releases summaries of the technical sections reviewed, they can fill in design details of the studies.

4.5 Conference materials, posters and theses

Presentations at veterinary conferences (for example, those of professional associations in veterinary medicine, parasitology, immunology, poultry science, swine health, cattle practice and companion animal practice) can include the earliest disclosure of a new technique. Whether such materials are printed publications depends on their accessibility:

  • Published proceedings and abstract books distributed to attendees, or posted online and indexed, are strong candidates.
  • Posters and oral presentations that were not published or indexed require a Klopfenstein-type factual analysis: the duration, audience, expectations of confidentiality, whether copying was permitted and whether handouts were available.
  • Theses and dissertations from veterinary schools and graduate programs are generally accessible once cataloged, with the date of cataloging being critical (Hall; Cordis).
  • Webcast or recorded presentations require evidence of the date and public access, for example from the host’s records.

4.6 Patents and patent applications

Earlier patent documents in the animal health field include those of companies, universities and government agencies. Searching patent classification schemes for veterinary medicine and for the relevant technology and using family and citation analysis, will identify relevant documents. Non-US documents (EP, WO and others) are prior art as of their publication date and should not be overlooked. Because patent documents in animal health are often adaptations of human-health patents, look in both fields.

4.7 International and non-government sources

  • The World Organisation for Animal Health (WOAH) manuals and standards and the work of the Food and Agriculture Organization of the United Nations (FAO).
  • The European Medicines Agency’s public assessment reports for veterinary medicines and national agency records (for example UK Veterinary Medicines Directorate and Canadian and Australian regulators).
  • Industry technical bulletins, product monographs and brochures, which can be highly specific but require evidence of their dates and distribution.
  • Veterinary Information Network and similar subscription services. Public accessibility will depend on the membership criteria and the practical availability to skilled persons; assess carefully.

5. Public use and on-sale in the animal health setting

Field work in animal health often involves third parties (producers, clinics, contract research organisations) and may involve commercial activity before filing. This can create statutory bars for the patentee and defenses for challengers:

  • Commercial sale of products and services. Sales of a veterinary product, an offer for sale, or a contract to supply may trigger the on-sale bar once the invention is ready for patenting and the subject of a commercial offer (Pfaff v. Wells Electronics, Inc., 525 U.S. 55 (1998); Helsinn).
  • Public use in field trials. Use by third-party farmers or veterinarians without confidentiality or control may be public use. Experimental use can negate a public-use claim where the inventor retains control and the use is for the purpose of testing. Evidence of confidentiality agreements, protocols, control and record-keeping matters (see the factors in Electromotive Division of General Motors Corp. v. Transportation Systems Division of General Electric Co., 417 F.3d 1203 (Fed. Cir. 2005)).
  • Regulatory approvals and exemptions. Investigational new animal drug (INAD) exemptions and USDA experimental biologics permits regulate how trials may be run. They do not in themselves create public disclosures, but the way the trials were organised (open enrolment, publicised results) can.
  • Licensing of biologics. The commercial release of a licensed vaccine is a public use and a sale and may disclose the product, though not necessarily the details of the formulation or manufacturing process. Reverse engineering and the disclosure in the product itself matter.

These theories must be supported with documentary and testimonial evidence. They are available in district court and in the ITC, but not in IPR or post-grant review based on prior art challenges to patents or printed publications only, as discussed below.

6. Procedural vehicles and how the evidence is used

ForumWhat prior art can be usedPoints for animal health references
District court (or ITC)All § 102 categories, including public use and on-sale. Invalidity must be proved by clear and convincing evidence (Microsoft Corp. v. i4i Ltd. Partnership, 564 U.S. 91 (2011)).Live testimony of custodians and scientists, expert reports on the state of the art and the skilled person and discovery of the patentee’s own field-trial and regulatory records.
Inter partes review (IPR)Only patents and printed publications (35 U.S.C. § 311(b)). Preponderance of the evidence standard.Journal articles, USDA publications and regulatory summaries are well-suited, but public use and sale evidence is not available as a ground, although it can be used to show the content of a printed publication or background knowledge.
Post-grant review (PGR)All grounds (including § 112 and public use or on-sale), but available only within nine months of grant of AIA patents.Useful for recently granted patents where on-sale or public-use evidence is available.
Ex parte reexaminationPatents and printed publications, raising a substantial new question of patentability.A lower-cost, anonymous option, but with no participation by the requester after filing.
European opposition (EPO)Any prior art made available to the public by any means before the filing or priority date (Article 54(2) EPC).The “any means” standard accepts oral disclosure and public use and prior art is assessed by the “gold standard” of directly and unambiguously derivable disclosure.

Note on IPR practice: The USPTO’s approach to discretionary denial of IPR petitions, including considerations of parallel litigation, the age of the patent and settled expectations, has changed several times in recent years. Check the current USPTO guidance, Director decisions and rules before planning an IPR strategy.

6.1 Building the evidentiary record

  1. Identify the critical date. Establish the effective filing date of each claim, including any priority claim and challenge the priority where the earlier document does not support the claims. A veterinary reference published between the priority date and the filing date can become prior art if the priority is not entitled.
  2. Establish the status of each reference. For each document, obtain proof of the date and public accessibility: publication date on its face, library catalog entry, publisher declaration, indexing records, web-archive evidence, or a custodian’s declaration.
  3. Prove the content. Obtain a complete copy (all pages, figures and tables) and, where necessary, a certified translation. A partial copy invites an argument that the document was not complete.
  4. Map the claims. Prepare a claim chart by element with citations to the references and distinguish disclosures by explicit teaching, inherent disclosure or motivation.
  5. Support with expert testimony. A veterinary scientist, pharmacologist, parasitologist or immunologist can explain the skilled person’s level and knowledge, species differences and the reasonable expectation of success. Choose an expert with credible hands-on experience in the relevant species.
  6. Address secondary considerations. Commercial success, long-felt need, failure of others, unexpected results and copying are frequently raised by patentees in animal health cases. Prepare responses, including evidence of nexus and evidence that the commercial success arises from other factors (marketing, a pre-existing active ingredient, regulatory exclusivity or blocking patents).
  7. Consider regulatory exclusivity and patent term. Animal drug patents may benefit from patent term restoration under 35 U.S.C. § 156 (for animal drugs, administered by the FDA with the USPTO) and approvals can carry marketing exclusivity independent of patents. These do not affect validity but are relevant to the commercial stakes and the timing of challenges.

7. Specific challenges and how to address them

ChallengeApproach
Dating a reference from a veterinary journal published online firstObtain the publisher’s date records (received, accepted, published online), DOI registration data and any archive or indexing records. A declaration from the publisher or the indexing service strengthens the evidence.
Conference abstract with limited detailUse it as evidence of the existence and teaching of the technique, in combination with a more detailed reference. Evaluate enablement and the amount of detail disclosed and consider whether the abstract supplies a reason to combine.
Undated USDA web contentDo not rely on it without a date. Use archived versions, NAL catalog records or the document’s own date. Where the content was updated, show the content as it stood at the critical date.
Patentee says species differences defeat the expectation of successGather species-specific literature, pharmacokinetic and pharmacodynamic data and the patentee’s own statements in the specification and prosecution history. Show where the specification itself treats species as interchangeable.
Patentee relies on unexpected resultsTest whether the data in the specification are commensurate in scope with the claims, compared with the closest prior art and statistically significant. Check the controls and the species, dose and endpoints used.
Reference is a regulatory summary lacking detailCombine it with veterinary pharmacology literature and the approved label. Argue that the summary supplies the key parameter (dose, species, indication) and the background literature supplies the rest.
Inventor’s own earlier publicationCheck the grace period (§ 102(b)(1)(A)): a disclosure by the inventor within one year before the effective filing date is not prior art. Third-party disclosures derived from the inventor are also excepted, so check authorship and whether the third party is a co-author or a collaborator.
Confidential data of competitor submitted to a regulatorConfidential regulatory submissions are not public and are not prior art. Look for what is made public (summaries, labels, notices) or obtain it through discovery for use in other ways, such as evidence of on-sale activity, where applicable.

8. A search strategy for animal health prior art

  1. Define the claims and the technology. Identify the active ingredient, the formulation, the species, the disease or condition, the dose and regimen, the delivery system and the claim limitations that distinguish the patent from the prior art.
  2. Build a vocabulary. Include synonyms, brand names, chemical names, CAS numbers, species names (common and Latin), breed and production-class terms and disease synonyms. Veterinary terminology varies by region and over time.
  3. Search multiple databases. Use PubMed/MEDLINE, CAB Abstracts (CABI), AGRICOLA and PubAg, Web of Science, Scopus, Embase, Google Scholar and national library catalogs. Add the FDA CVM and APHIS CVB websites and the Federal Register for regulatory documents.
  4. Search patent databases. Use full-text patent searches on both the human and animal fields, including non-US and non-English patents and applications. Use citation chaining forward and backward.
  5. Search grey literature. Conference proceedings, theses (ProQuest, university repositories), extension publications, company technical bulletins and trade press.
  6. Search the web archive carefully. Web-archive captures can prove the date and content of web material, but they require authentication and the completeness of the capture can be contested.
  7. Check the family of the patent and its citations. The patent’s own prosecution history, the references cited by the examiner and in related applications and the patentee’s IDS show what was before the examiner. Art not before the examiner is more persuasive in an IPR and may carry more weight in court, although the burden remains the same in court.
  8. Interview the field. Retired government scientists, veterinarians, extension agents and industry experts can point to material that is not indexed. Verify and document anything you find.
  9. Document the search. Keep a record of search strings, databases, dates and results, which will help in litigation, in preparing declarations and in responding to any challenge to the thoroughness of the search.

9. Defensive perspective: for patentees and applicants

Applicants in animal health can use the same understanding to strengthen their patents:

  • Search veterinary literature and USDA sources as well as patent databases before filing and cite what is found in an IDS to meet the duty of candour.
  • Avoid publishing, presenting, selling or field-testing before filing, or manage the grace period carefully. In jurisdictions with no grace period, such as the EPO, any prior disclosure by the inventor can be fatal.
  • Use confidentiality agreements and controlled protocols for field trials and keep records to support an experimental-use position.
  • Include data on species, dose and regimen in the specification and show how results in one species relate to another, so that claims to other species are supported and obviousness arguments based on species differences are anticipated.
  • Record the dates and details of conference presentations and journal submissions, so you can rely on the grace period or establish that a disclosure was not public.
  • Prepare evidence of secondary considerations early, such as unexpected results from comparative studies, commercial data with nexus to the claims and any copying or industry praise.

10. Conclusion

Veterinary literature and USDA research are rich sources of prior art for challenging animal health patents and they are often underused because they are scattered, dated unevenly and indexed in specialist databases. A successful invalidity case builds from three foundations: a reference that is demonstrably public and demonstrably dated, a clear reading of what it teaches to a skilled person in the relevant species and a credible explanation of why the claimed invention was an obvious or anticipated step. Evidence of dates and accessibility, species-specific expertise and a complete record should be developed at the start, not at the end, of the project.

Leave a Reply

Your email address will not be published. Required fields are marked *